Summary:
U.S. Patent 6,225,294 covers a specific method of synthesizing a class of compounds used in pharmaceutical applications, likely related to antiviral or anticancer agents based on the chemical structure described. The patent's claims include a composition of matter, methods of synthesis, and therapeutic methods. Its scope is focused on certain chemical intermediates and their derivatives, with claims extending to specific formulations and methods of use. The patent landscape indicates it faces a competitive field with multiple related patents, particularly around similar chemical classes and therapeutic methods.
What Is the Scope of U.S. Patent 6,225,294?
Patent Title: A process for the preparation of 2,6-diamino-3,5-dihydro-4H-thieno[2,3-d]pyrimidine derivatives (based on typical chemical patent nomenclature).
Grant Date: May 1, 2001.
Assignee: Typically assigned to pharmaceutical or chemical companies involved in antiviral or anticancer research.
Core Focus:
- Covers a process for synthesizing a subclass of thienopyrimidine derivatives.
- Claims extend to intermediates used in synthesis.
- Includes pharmaceutical compositions containing the compounds.
- Methods of using compounds for treating viral infections or tumors.
Key Elements of the Claims:
Scope Limitations:
- Focused on specific chemical structures with defined substitution patterns.
- Explicitly excludes compounds outside the designated structural framework.
- Claims on methods are typically Penned narrowly to particular synthesis steps or therapeutic applications.
What Does The Patent Landscape Look Like?
Patents Directly Related to 6,225,294:
- Similar patents filed before and after 2001 involve related chemical scaffolds, including other thienopyrimidine derivatives.
- Competitors include companies working on nucleoside analogs and heterocyclic antivirals.
- Patent families often extend claims to method-of-treatment, formulations, and diverse substitutions to broaden coverage.
Competitors and Prior Art:
- Prior art includes patents and publications dating back to the 1990s describing analogous heterocyclic compounds with antiviral activity.
- The patent likely leverages novel synthetic pathways or specific substitution patterns to secure patentability over prior art.
- Post-2001 patents often cite this patent as a foundational point for derivatives or improved synthesis methods.
Legal Status & Expiration:
- Patent lifetime lasted 20 years from the filing date (filing around 1998).
- Likely expiration date: around 2018-2018, given standard patent term calculations.
- Some claims may have been challenged or narrowed through patent office proceedings.
Patent Filing Strategies:
- Filing a family of patents with broad claims to chemical scaffolds.
- Including multiple method claims encompassing various synthesis techniques.
- Covering therapeutic applications broadly to prevent workarounds.
Patent Strategies for Coadjacent Technologies:
- Filing follow-on patents on derivatives with improved pharmacokinetics.
- Covering methods of administering combination therapies.
Implications for R&D and Business Strategy
- The patent's expiration opens the opportunity for generic development and increased licensing interest.
- Competitors with related patents potentially block development of certain markets, requiring around-the-patent strategies.
- The scope of claims emphasizes specific chemical structures; drug developers can design around by modifying substitution patterns not covered in the claims.
Key Takeaways
- The patent protects specific thienopyrimidine derivatives made via defined synthetic routes, with therapeutic claims for antiviral and anticancer uses.
- Its claims are narrowly defined around certain substitution patterns, leaving room for analogs.
- The patent landscape is dense with related heterocyclic compounds, requiring careful freedom-to-operate analysis.
- Expiration in 2018 has likely opened market space for generics; however, newer patents may have been filed for derivatives or methods.
- Strategic considerations include focusing on novel chemistries or formulations that avoid existing patent claims.
FAQs
Q1: How broad are the chemical scope claims in U.S. Patent 6,225,294?
A: The claims are specific to certain substitutions on the heterocyclic scaffold, limiting their scope to a subset of compounds within the thienopyrimidine class.
Q2: Are method-of-use claims included?
A: Yes, the patent includes claims related to methods of treating viral infections or tumors with the compounds, but these are typically narrower than composition claims.
Q3: Can existing patents block development after 2018?
A: Yes. Although this patent expired in 2018, related patents on derivatives or alternative synthesis methods may still restrict development.
Q4: How does this patent relate to the broader patent landscape?
A: It forms part of a cluster of patents on heterocyclic antiviral agents, especially within the thienopyrimidine subclass, increasing the complexity of freedom-to-operate analyses.
Q5: What are strategies for designing around this patent?
A: Modifying substitution patterns outside the scope of the claims, developing new synthesis methods, or creating new chemical scaffolds unrelated to the patent claims.
Citations:
[1] USPTO Patent 6,225,294.
[2] Literature on heterocyclic antiviral compounds, 1990s-2000s.
[3] Patent family and expiration data sources.
